Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study
REIMAGINE 2 was a 68-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and placebo in 2,713 adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor
It is typically administered as a subcutaneous injection based on a clinician-directed plan
Batalova GA, Krasilnikov VN, Popov VS, Safonova EE
Second, on January 1, 2026 the OSU Health Plan discontinued GLP-1 weight-management coverage with no exceptions, citing unsustainable cost only Type 2 diabetes use is now covered
For this reason, the subcutaneous route remains the only clinically validated method of administration